CN1193790C - 胸腺肽组合物注射剂及其制备方法 - Google Patents
胸腺肽组合物注射剂及其制备方法 Download PDFInfo
- Publication number
- CN1193790C CN1193790C CN 02123538 CN02123538A CN1193790C CN 1193790 C CN1193790 C CN 1193790C CN 02123538 CN02123538 CN 02123538 CN 02123538 A CN02123538 A CN 02123538A CN 1193790 C CN1193790 C CN 1193790C
- Authority
- CN
- China
- Prior art keywords
- thymosin
- injection
- sodium chloride
- composition
- reduced glutathion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002347 injection Methods 0.000 title claims abstract description 28
- 239000007924 injection Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 108010046075 Thymosin Proteins 0.000 title claims description 35
- 102000007501 Thymosin Human genes 0.000 title claims description 35
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title claims description 35
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 56
- 239000011780 sodium chloride Substances 0.000 claims description 26
- 235000003969 glutathione Nutrition 0.000 claims description 23
- 229960003180 glutathione Drugs 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 16
- 239000008215 water for injection Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 235000010265 sodium sulphite Nutrition 0.000 claims description 8
- 239000002158 endotoxin Substances 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 239000008354 sodium chloride injection Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 9
- 108010024636 Glutathione Proteins 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 208000030961 allergic reaction Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000002992 thymic effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000005457 optimization Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02123538 CN1193790C (zh) | 2002-07-01 | 2002-07-01 | 胸腺肽组合物注射剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02123538 CN1193790C (zh) | 2002-07-01 | 2002-07-01 | 胸腺肽组合物注射剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1398636A CN1398636A (zh) | 2003-02-26 |
CN1193790C true CN1193790C (zh) | 2005-03-23 |
Family
ID=4745153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02123538 Expired - Fee Related CN1193790C (zh) | 2002-07-01 | 2002-07-01 | 胸腺肽组合物注射剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1193790C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101380461B (zh) * | 2008-09-27 | 2011-09-07 | 吴建中 | 高效的胸腺肽肠溶片和注射用胸腺肽 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840177B (zh) * | 2006-01-11 | 2011-04-06 | 成都圣诺科技发展有限公司 | 胸腺肽α1注射液及其制备方法 |
CN102579347B (zh) * | 2012-03-02 | 2013-03-06 | 海南灵康制药有限公司 | 一种注射用胸腺法新脂质体制剂 |
CN104840418B (zh) * | 2015-06-11 | 2018-01-12 | 山东新时代药业有限公司 | 一种盐酸法舒地尔注射液组合物及其制备方法 |
-
2002
- 2002-07-01 CN CN 02123538 patent/CN1193790C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101380461B (zh) * | 2008-09-27 | 2011-09-07 | 吴建中 | 高效的胸腺肽肠溶片和注射用胸腺肽 |
Also Published As
Publication number | Publication date |
---|---|
CN1398636A (zh) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1193790C (zh) | 胸腺肽组合物注射剂及其制备方法 | |
CN1195544C (zh) | 用于慢性肝炎的肝功能改善剂 | |
CN1803811A (zh) | 一类硝基咪唑衍生物、制备方法及用途 | |
CN1186094C (zh) | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 | |
CN1429558A (zh) | 甘露聚糖肽注射液及其制备方法和使用方法 | |
CN101019869B (zh) | 前列地尔和穿琥宁/炎琥宁脂质体组合药物及其制备方法 | |
CN1795002A (zh) | 用于治疗癌症的基于岩石粉、更具体是白云石粉的药物 | |
AP1168A (en) | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets. | |
CN1111411C (zh) | 一种抗菌用的克林霉素磷酸酯粉针剂及其制备方法 | |
CN1833721A (zh) | 一种胸腺五肽与干扰素的组合物 | |
CN101073572A (zh) | 一种治疗风寒湿痹症的药物组合物及其制备方法 | |
CN1686179A (zh) | 垂体前叶肾上腺皮质提取物纳米脂质体组合药物及其制备方法和用途 | |
CN1806801A (zh) | 一种治疗呼吸道感染的新鱼腥草素钠的药物组合物及其制备方法 | |
CN1895276A (zh) | 用于治疗血小板减少的注射用药物 | |
CN1839842A (zh) | 一种含左西孟旦或其药学上可以接受的盐作为活性成分的药物组合物 | |
CN1730014A (zh) | 苦木注射剂新的给药途径及其制备工艺、新的适应症 | |
CN1415301A (zh) | 含有苦参素、前列腺素e1和阿司匹林的复方制剂及其制备方法和用途 | |
CN1189167C (zh) | 复方氨基酸注射液及其制造方法 | |
CN1070053C (zh) | 注射用盐酸丁卡因的制备方法 | |
CN1768762A (zh) | 鹿茸精注射剂新的给药途径及其制备工艺、新适应症 | |
CN1663610A (zh) | 溶菌酶新制剂 | |
CN1136849C (zh) | 替硝唑胃漂浮缓释胶囊及其制备方法 | |
CN100335038C (zh) | 含有生物活性物质和中药成分包封的无机盐纳米粒子的制备方法 | |
CN1679914A (zh) | 还原型谷胱甘肽和依布硒啉的组合药物 | |
CN1732912A (zh) | 一种不含辅料的硫普罗宁静脉注射用冻干制剂及制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hunan Kangyuan Pharmacy Co., Ltd. Assignor: Cai Haide Contract record no.: 2011430000207 Denomination of invention: Thymosin composition injection and its prepn Granted publication date: 20050323 License type: Exclusive License Open date: 20030226 Record date: 20111008 |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN KANGYUAN PHARMACY CO., LTD. Free format text: FORMER OWNER: CAI HAIDE Effective date: 20120306 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 330009 NANCHANG, JIANGXI PROVINCE TO: 410329 CHANGSHA, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120306 Address after: 410329 No. 36, link road, A District, Liuyang biomedical industry park, Hunan Patentee after: Hunan Kangyuan Pharmacy Co., Ltd. Address before: 330009, room 11, 201 Bai Yi lane, Xiangshan South Road, Nanchang, Jiangxi Patentee before: Cai Haide |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050323 Termination date: 20140701 |
|
EXPY | Termination of patent right or utility model |